Figure 2.

Post-transplant outcomes for 743 adults with AML undergoing allogeneic HCT while in first or second morphologic remission, stratified by conditioning intensity and pre-transplant MRD status. (A) Cumulative risk of relapse. (B) Relapse-free survival, (C) Overall survival. (D) Cumulative risk of non-relapse mortality. Outcome estimates are shown separately for MAC patients in MRD^neg remission (n = 345) or MRD^pos remission (n = 96), RIC patients in MRD^neg remission (n = 106) or MRD^pos remission (n = 24), and NMA HCT patients in MRD^neg remission (n = 145) or MRD^pos remission (n = 27), respectively.